First Trust NYSE Arca Biotech Index Fd

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Veracyte Receives Medicare Coverage for Bladder Cancer Test, Orders Open June 1

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

Arrowhead Advances RNAi Pipeline, REDEMPLO Launches with Over 400 Prescriptions in First Quarter

Illumina CEO joins China delegation, stock price rises

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Axsome Therapeutics Receives FDA Approval for AUVELITY

Mizuho Raises Axsome Therapeutics Price Target to $310

Leqembi® Iqlik™ PDUFA date updated to August 24th

FDA Prioritizes Review of LEQEMBI® IQLIK™ Subcutaneous Injection for Early Alzheimer's Disease

Arrowhead Pharmaceuticals Announces Q2 2026 Earnings Report with Increased Net Loss

Arrowhead Pharmaceuticals Q2 Revenue Falls Short of Estimates

ArrowHead Pharma released FY2026 Semi-Annual earnings on May 7 During-Market (EST), actual revenue USD 337.77 M, actual EPS USD -0.73

ArrowHead Pharma released FY2026 Q2 earnings on May 7 During-Market EST, actual revenue USD 73.74 M (forecast USD 71.71 M), actual EPS USD -0.9319 (forecast USD -1.115)

Amesite

Meiwu Tech

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Co-Diagnostics

MetaVia

Phoenix Asia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Gen Digital - Rights

Pinned News

置顶新闻

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

HOTH

LABU

Hoth Therapeutics Inc. plans to rebrand as Rocket One Inc. to focus on AI semiconductor technologies and ultra-low-power AI computing. The board unanimously approved this strategic shift, which includes securing exclusive rights to technologies from Virginia Commonwealth University. The company will maintain its biotechnology operations while addressing AI infrastructure challenges. Hoth's shares fell 9.69% to $0.55 in premarket trading, reflecting a 20.9% decline over the past month.

benzinga_article

Hoth Therapeutics

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

S&P 500

SBFM

SBFMW

SBIO

ARKG

Sunshine Biopharma has successfully closed a public offering, raising approximately $6 million. The deal included 12 million common or pre-funded units priced at $0.5 each, bundled with two Series C warrants. These warrants are immediately exercisable at $0.5 for five years, potentially generating an additional $12 million. The net proceeds will be used for general corporate purposes and working capital.

PUBT

Sunshine Biopharma

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

ACCESS Newswire

Sunshine Biopharma closes USD 6 million public offering with Series C warrants

CBUS

Cibus (CBUS) reported a Q1 2026 net loss of $21.2 million, significantly reduced from $49.4 million year-over-year. The company raised $37 million to support its commercial objectives, with a cash position of $30.3 million. Key developments include a planned 2027 Latin America rice launch and expanded partnerships in sustainable ingredients. Regulatory progress in Ecuador and Peru supports market access, while U.S. launch delays to 2029 are noted. Management emphasizes cost discipline and a financial runway extending into Q1 2027.

Motley Fool

Cibus

Cibus (CBUS) Q1 2026 Earnings Transcript

NBTX

Qube Research & Technologies has disclosed a 0.58% net short position in Nanobiotix shares, as per an AMF filing.

Nanobiotix SA

Qube Research & Technologies discloses net short position in Nanobiotix shares

ABVX

D.E. Shaw disclosed a 1.24% net short position in Abivax shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Abivax SA

Health Care Select Sector SPDR

VG Health

iShares US Pharma

D.E. Shaw discloses net short position in Abivax shares

.DJI

.IXIC

.SPX

U.S. stocks are mostly lower as Treasury yields continue to rise. The Nasdaq has notably declined by 1% to 25,821.67, while the S&P 500 and Dow are down 0.7% and 0.4%, respectively. Despite being off their session lows, all major averages remain in negative territory.

- Stocks generally moved lower on Tuesday, with major indices experiencing declines after a mixed performance the previous day.  
- The Nasdaq fell by 269.07 points (1 percent), while the S&P 500 decreased by 50.58 points (0.7 percent), and the Dow dropped 175.35 points (0.4 percent).  
- Although the major averages are off their session lows, they remain in negative territory.

rttnews

Dow Jones Industrial Average

NASDAQ Composite Index

Invesco QQQ Trust

ISHRS Russ 1000 Growth

Guggenheim DJIA Ave Div

VanEck Semiconductor ETF

VG Growth

First Trust NASDAQ-100 Equal Weighted

Direxion S&P 500 Bull 2X

iShares Dow Jones US

ProShares Ultra Dow30 ETF

Schw Us L-Cp Grw

SPDR S&P 500

Proshares UltraPro QQQ

VG Value

Pro UltrPro Dow30

VG S&P 500

VG Mga Cap 300 Grw

ProShares Ultra QQQ

Direxion Semicon Bull 3X

Direxion S&P 500 Bull 3X

Invesco Nasdaq 100 ETF

Fidelity Nasdaq Composite Index ETF

iShares Core S&P 500

iShares Core S&P US Growth

SPDR Djia

iShares Semiconductor ETF

U.S. Stocks Mostly Lower As Treasury Yields Extend Recent Surge

ABBV

In today's trading, U.S. semiconductor stocks like Nvidia and AMD saw significant declines, while the healthcare sector, led by Eli Lilly and AbbVie, showed gains. The market sentiment is cautious due to concerns over the global chip shortage, but optimism in healthcare suggests a shift in investor interest. Recommendations include increasing healthcare allocations and considering semiconductor stocks for risk-tolerant investors, emphasizing the importance of diversification.

- The U.S. stock market showed mixed results, with technology stocks, notably semiconductors like Nvidia and AMD, experiencing declines amid pressures in the industry.  
- In contrast, the healthcare sector thrived with gains from Eli Lilly and AbbVie due to strong earnings and positive clinical news, attracting investor interest.  
- Strategic recommendations suggest investors increase healthcare sector allocations while considering the semiconductor weaknesses as potential buying opportunities for those willing to endure short-term fluctuations.

Investinglive

Abbvie

Eli Lilly

T-Rex 2X Inverse NVIDIA Daily Target ETF

Direxion Daily NVDA Bear 1X ETF

Invesco Nasdaq Biotechnology ETF

Direxion Daily NVDA Bull 2X Shares

iShares Global Healthcare

GraniteShares 2x Long NVDA Daily ETF

Direxion Semicon Bear 3X

Direxion Daily AMD Bear 1X Shares

Direxion Daily AMD Bull 2X Shares

Direxion Daily LLY Bull 2X Shares

AXS 1.5X NVDA Bear Daily ETF

GraniteShares 2x Long AMD Daily ETF

GraniteShares 2x Short NVDA Daily ETF

NVIDIA

Intel

NVIDIA Corporation

Tech turmoil: Semiconductor stocks slide, healthcare finds footing

INCY

LABD

Incyte Stock: Analyst Estimates & Ratings

Barchart Option

Incyte

Direxion S&P Biotech Bear 3X

Incyte Stock: Analyst Estimates & Ratings

GILD

Daiwa Securities Group has lowered its target price for Gilead Sciences (NASDAQ:GILD) from $161.00 to $150.00 while maintaining an 'outperform' rating. This new target suggests a potential upside of 14.66%. Other analysts have varied opinions, with Barclays setting a $155.00 target and Wells Fargo raising theirs to $165.00. Gilead's stock is currently trading at $130.82, with a market cap of $162.42 billion and a P/E ratio of 17.85.

Market Beat

Gilead Sciences

Daiwa Securities Group Inc.

Barclays

Wells Fargo

Mizuho Financial

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Mizuho Financial Group, Inc.

Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

NTHI

Maxim Group, Alliance Global Partners, and BTIG Research have initiated coverage of NeOnc Technologies, all providing favorable ratings and price targets. This increased analyst attention comes ahead of the anticipated interim Phase 2a data for the lead candidate NEO100.

Neonc Tech

Maxim Group, Alliance Global, BTIG initiate coverage of NeOnc Technologies

STRO

Duality Biotherapeutics has announced a share buyback plan of up to USD 40 million, funded from internal resources, with shares to be held as treasury stock. Chairman and CEO Zhu Zhongyuan will also purchase up to USD 5 million in shares using personal funds. The announcement was made on May 19, 2026.

Sutro Biopharma

DUALITYBIO-B

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

Duality Biotherapeutics plans share buyback of up to US$40 million

First Trust NYSE Arca Biotech Index Fd(FBT.US)

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

Sunshine Biopharma closes USD 6 million public offering with Series C warrants

Cibus (CBUS) Q1 2026 Earnings Transcript

Qube Research & Technologies discloses net short position in Nanobiotix shares

D.E. Shaw discloses net short position in Abivax shares

U.S. Stocks Mostly Lower As Treasury Yields Extend Recent Surge

Tech turmoil: Semiconductor stocks slide, healthcare finds footing

Incyte Stock: Analyst Estimates & Ratings

Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Maxim Group, Alliance Global, BTIG initiate coverage of NeOnc Technologies

Duality Biotherapeutics plans share buyback of up to US$40 million